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TAKE HOME MESSAGE 
Circulating microRNA-371a-3p levels accurately predict viable germ cell tumor (GCT) in 
chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection with >90% 
sensitivity and specificity. MiRNAs are a promising candidate biomarker to detect occult disease 
and change clinical practice in early-stage GCT. 
Take Home Message
Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve 
patients undergoing retroperitoneal lymph node dissection 
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Serum-based biomarkers (α-fetoprotein (AFP), ß-human chorionic gonadotropin (ß-hCG), and 
lactate dehydrogenase (LDH) are integral in the diagnosis, management, and follow-up of 
patients with testicular germ cell tumors (GCTs). The clinical utility of these markers is 
tempered by limited sensitivity and specificity, as they are expressed in only a subset of GCTs 
and may be normal in the setting of early recurrence or low tumor burden (marker-negative, 
radiographically occult metastases). Serum microRNAs (miRNAs; miR-)—small noncoding 
RNAs involved with epigenetic regulation of gene expression—are emerging as candidate 
biomarkers for diagnosing and monitoring viable GCT, regardless of histology.1,2  The capacity 
of miRNA to predict viable GCT in chemotherapy-naïve patients has not been explored.  The 
ability to accurately personalize the decision to forego or pursue primary treatment 
(retroperitoneal lymph node dissection (RPLND), chemotherapy, or radiotherapy) in a cohort of 
patients arguably best suited for surveillance would mitigate the morbidity associated with 
overtreatment.  Herein, we evaluate the performance characteristics of serum miRNA levels to 
predict viable GCT in chemotherapy-naïve patients undergoing primary RPLND.  
 
We prospectively collected serum samples from consecutive chemotherapy-naïve patients with 
Type II GCT undergoing primary RPLND at our institution between 2016 and 2019 immediately 
prior to surgery.  Preoperative cross-sectional staging imaging and conventional STMs were 
obtained within 10 days of surgery, and all patients were either clinical stage I or II with no 
radiographic evidence of distant metastases.  Bilateral full-template or extended modified 
template (extending to the contralateral ureter above the inferior mesenteric artery) nerve-sparing 
RPLND was performed.  RNA extraction, initial QC, and serum miRNA quantification were 
completed as described by Murray et al.3  RPLND histology was classified as either benign, 
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viable GCT, or teratoma only.  Corresponding performance characteristics (area under the curve 
(AUC) analysis of receiver-operator characteristic (ROC) curves, accuracy, sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV)) were 
calculated for each miRNA signature.   
 
Our cohort consisted of 24 total patients with clinical stage I (50%) or II (50%) GCT undergoing 
primary RPLND.  Orchiectomy histology was pure seminoma in 4 patients (16.7%), NSGCT in 
18 patients (75%), and burned-out tumor in 2 patients (8.3%) with clinical stage II disease.  Final 
RPLND histology was benign in 10 patients (41.7%), pure teratoma in 3 patients (12.5%), and 
viable GCT in 11 patients (45.8%). Seminoma and teratoma were identified on RPLND for 
patients with burned-out primary. The smallest foci of viable GCT identified were, in some 
cases, less than 5 mm.  Four patients (16.7%) received chemotherapy post-RPLND, including 
one that recurred, one patient with limbic encephalitis paraneoplastic syndrome and two patients 
with N2 NSGCT who received adjuvant chemotherapy.  Out of the prototypical 4-member 
putative serum miRNA panel for detection of GCT, miR-371a-3p has consistently been the most 
sensitive.2,4 We also included miR-375 in our panel due to a recent report indicating high 
expression in teratoma tissue 5. To determine if serum miR-371a-3p predicts the presence of 
viable GCT in RPLND, patients were divided into three groups based on RPLND pathology: 
benign, pure teratoma, or viable GCT.  miR-371a-3p was the most discriminatory serum miRNA 
for viable GCT, exhibiting ~13,000-fold increase in expression over teratoma or benign 
pathology. On ROC analysis, miR-371a-3p had AUC=0.965, with sensitivity and specificity of 
100% and 92%, respectively.  The AUC for other serum miRNAs in predicting viable GCT were 
0.874 (miR-367-3p), 0.846 (miR-372-3p), and 0.720 (miR-373-3p). Performance of miR-371a-
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3p did not differ significantly from the full panel (p > 0.05). These serum miRNAs, including 
miR-375, were not predictive of pure teratoma.   
 
In this prospective study, we found that miR-371a-3p exhibited striking performance 
characteristics to accurately discriminate viable GCT from benign processes or pure teratoma in 
patients undergoing primary RPLND with normal STMs.  miR-371a-3p yielded an AUC of 
0.965 and a sensitivity and specificity of 100% and 92%, respectively, at a threshold of 2-fold 
over normal serum. Elevations of miR-371a-3p were present in the setting of both non-
teratomatous NSGCT and pure seminoma, despite normal conventional STMs.  These novel 
results demonstrate strong performance characteristics for miR-371a-3p in the detection of occult 
or low-volume retroperitoneal disease.  Despite being limited by small numbers and inability to 
sub stratify, if validated in larger cohorts, these data suggest a basis to revolutionize how patients 
with early stage GCT are treated.  No other studies have described data regarding performance 
characteristics of miRNAs with pathologic confirmation of the presence or absence of small 
volume metastatic disease in the context of negative STMs.  Two large clinical trials 
[AGCT1531 (NCT03067181) and SWOG-S1823] are accruing and expected to open soon, 
respectively, to further study the role of miRNAs in patients with early stage disease.  More 
recently, in the largest prospective study to evaluate the performance of miR-371a-3p as a 
biomarker in GCT, Dieckmann et al. reported 90% sensitivity, 94% specificity, 97% PPV, 83% 
NPV, and an AUC of 0.966 for the primary diagnosis of malignant GCT, similar to the 
performance characteristics reported in our study.2  Our study is unique in that we were able to 
pathologically verify the presence or absence of viable GCTs prior to clinical relapse.    
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Our data suggest excellent performance characteristics of miRNAs, particularly miR-371a-3p, to 
accurately differentiate small-volume viable GCT from benign processes or pure teratoma in 
patients undergoing primary RPLND, with an AUC of 0.965 and >90% sensitivity and 
specificity. Although none of these miRNA accurately predicted teratoma, our dataset was small 
and evaluation of miR-375 is still in early stages. If validated in larger cohorts, these data suggest 
a basis to implement precision medicine strategies in patients with early stage GCTs. Due to the 
early stage of this work and the technical expertise required, current clinical decision making 
should not rely upon miRNA assay results. 
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A) Top: Serum miR-371a-3p expression relative to normal serum. Symbols represent outliers as 
determined by Tukey’s method. Bottom: ROC curve of miR-371a-3p. B) Summary table of 
results. Green box with check indicates a positive result (relative expression over threshold), blue 
box with dash indicates negative result. Thresholds and performance metrics are outlined in 
Supplementary Table 1. C) Graphical summary. Serum was taken immediately prior to RPLND 
for RNA extraction and RT-PCR. Results were compared to RPLND pathology. miR-371a-3p 
summarized results and performance metrics are reported below. 


















































— — — — — — — — — — — —
Sensitivity: 100% Specificity: 92%
Viable GCT Teratoma Benign
miR-371a — — — — — — — — — — — —
miR-367 — — — — — — — — — — — — — — — — —
miR-372 — — — — — — — — — — — — —
miR-373 — — — — — — — — — — — — — — — — — —
miR-375 — — — — — — — — — — — — — — —
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